The global Barrett’s esophagus with dysplasia treatment market is poised for growth, projected to increase from a valuation of USD 4.5 million in 2023 to approximately USD 7.54 million by 2033. This expansion, expected at a CAGR of 5.3% from 2023 to 2033, is driven by a rising prevalence of Barrett’s esophagus (BE) and the critical need for early intervention to prevent progression to esophageal cancer. From 2018 to 2022, the market registered a steady CAGR of 3.2%, underscoring the growing demand for effective management of BE with dysplasia.
Barrett’s esophagus is a condition characterized by changes in the lining of the esophagus, making it more similar to intestinal lining and increasing cancer risk. Dysplasia, often a precursor to esophageal cancer, makes timely intervention essential. The market for treating BE with dysplasia includes a range of medical therapies and procedures aimed at preventing cancer and improving long-term patient outcomes.
With advancements in diagnostics and treatment methods, the market for Barrett’s esophagus with dysplasia treatment is set to offer improved options for patients and healthcare providers, enhancing preventative care and quality of life for individuals at risk of esophageal cancer.
What are the Challenges Faced by Barrett’s Esophagus with Dysplasia Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
The cost of treatment for Barrett’s esophagus with dysplasia can be high, particularly for advanced cases that require more invasive procedures. This can make it difficult for some patients to afford treatment, which can limit market growth.
Additionally, despite increasing awareness of Barrett’s esophagus with dysplasia, there is still a lack of knowledge and understanding about the condition among the general population. This can lead to delays in diagnosis and treatment, which can impact the growth of the market.
Moreover, the regulatory requirements for approval of new treatments for Barrett’s esophagus with dysplasia can be stringent, which can limit the number of treatments that make it to market. This can impact the availability of new and innovative treatments for patients.
Market Competition
Key players in the market include companies such as Competition Deep Dive, GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., In, AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., Abbott, AbbVie Inc., along with healthcare providers and technology companies among other global players.
- In August 2022, the American College of Gastroenterology released new guidelines for Barrett’s esophagus, which suggest expanding the screening methods beyond endoscopic procedures, increasing the frequency of surveillance for short-segment Barrett’s esophagus, and implementing volume criteria for endoscopic therapy centers.
- These guidelines were developed by a team of researchers from the University of North Carolina at Chapel Hill, and cover the definition and diagnosis of Barrett’s esophagus, screenings for esophageal adenocarcinoma, surveillance for known Barrett’s esophagus, and medical and endoscopic treatments for Barrett’s esophagus and early neoplasia.
- The authors emphasize that these guidelines should be used as a support for clinical practice and that healthcare providers should take into account patient-specific medical conditions, health status, and preferences to provide patient-centered care.
Key Companies Profiled
- GSK Plc.
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- Merck & Co. Inc.
- AstraZeneca
- Johnson & Johnson Private Limited
- Cipla Inc.
- Abbott
- AbbVie Inc.
Key Segments Profiled in the Barrett’s Esophagus with Dysplasia Treatment Industry Survey
Type:
- Low Grade Dysplasia
- High Grade Dysplasia
Treatment:
- Endoscopic Resection
- Radiofrequency Ablation
- Esophagectomy
- Photodynamic Therapy
- Cryotherapy
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube